Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Overview

This is a phase 1 study of the combination of cedazuridine with decitabine in patients with solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal hypomethylation and toxicity (up to 30 patients total).

Full Title of Study: “A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2022

Interventions

  • Drug: Decitabine
    • DOSING REGIMEN(S): Level -1 10mg daily days 1-4 Level 1 10mg daily days 1-5 Level 2 15mg daily days 1-5 Level 3 20mg daily days 1-5
  • Drug: Cedazuridine
    • DOSING REGIMEN(S): Level -1 100mg daily days 1-4 Level 1 100mg daily days 1-5 Level 2 100mg daily days 1-5 Level 3 100mg daily days 1-5

Arms, Groups and Cohorts

  • Experimental: Decitabine and Cedazuridine
    • Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.

Clinical Trial Outcome Measures

Primary Measures

  • Safety and tolerability of combination cedazuridine with decitabine as assessed by number of participants who experience adverse events
    • Time Frame: up to 2 years
    • Number of participants who have experienced grade 3 or higher adverse events, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
  • Maximum Tolerated Dose (MTD) as determined by number of participants with of dose limiting toxicities (DLT)
    • Time Frame: up to 2 years
    • Maximum tolerated dose will be determined by the maximum dose at which the least number of participants experience dose-limiting toxicity. The dose limiting toxicity is defined using the Common Terminology Criteria for Adverse Events (CTCAE).

Secondary Measures

  • Pharmacokinetics of ASTX727 in solid tumor patients as measured by total exposure
    • Time Frame: Day 2
    • Total exposure will be calculated as area under the plasma concentration-time curve (AUC) by using non-compartmental methods (Winonlin, version 5.3 or newer) and/or compartmental modeling (Adapt II, release 4.0)
  • Pharmacokinetics of ASTX727 in solid tumor patients as measured by maximum concentration (Cmax)
    • Time Frame: Day 2
    • Cmax (mmol/L) is defined as the maximum concentration of ASTX727 in blood.
  • Pharmacokinetics of ASTX727 in solid tumor patients as measured by time to maximum concentration (Tmax)
    • Time Frame: Day 2
    • Tmax (minutes) is defined as the time to reach maximum concentration of ASTX727 in blood.
  • Objective response rate (ORR) in solid tumor patients who are treated with ASTX727
    • Time Frame: up to 2 years
    • Proportion of participants who had measurable disease at baseline and have been re-evaluated after at least 1 cycle of therapy with observed reduction in tumor burden as defined by RECIST 1.1: Complete response (CR)= disappearance of all target lesions, Partial response (PR)= at least 30% decrease in sum of diameters of target lesions

Participating in This Clinical Trial

Inclusion Criteria

  • Participants must have advanced, unresectable, and/or metastatic solid tumor malignancy that is histologically or cytologically confirmed. – Patients must have received at least 2 lines of therapy in the advanced/metastatic setting (if 2 lines exist) and have no other possible therapies or refuse therapies that have shown clinical benefit for their condition. – ECOG performance status <1 – Ability to understand and the willingness to sign a written informed consent document. – Patients must have measurable disease – Ability to swallow oral medications Exclusion Criteria:

  • Participants who have had chemotherapy or radiotherapy within 3 weeks – Participants may not be receiving any other investigational agents. – Active hepatitis B or hepatitis C infection. – Active or untreated gastric or duodenal ulcer – Symptomatic bowel obstruction within 3 months prior to screening visit. – Symptomatic ascites in the last 4 weeks Other protocol defined inclusion/exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Collaborator
    • Astex Pharmaceuticals, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nilofer Azad, MD, Principal Investigator, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Overall Contact(s)
    • Jennifer Hale, 410-502-5140, phase1trials@jhmi.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.